RAD52 inhibitor program / Pathos - LARVOL DELTA

Rain Therapeutics Reports First Quarter 2021 Financial Results and Highlights Recent Progress (GlobeNewswire) - "'We are thrilled with the progress made so far this year, which included the successful completion of our IPO in April 2021...The net proceeds from the IPO position Rain well to execute on our pipeline of precision oncology programs, led by RAIN-32, an oral MDM2 inhibitor.'...Anticipated Near-term Milestones...RAIN-32 WD/DD Liposarcoma...Phase 3 trial start expected to commence in 2H 2021; RAIN-32 MDM2 Basket Study...Phase 2 trial start expected to commence in 2H 2021; RAIN-32 Intimal Sarcoma...Phase 2 trial start expected to commence by early 2022; RAD52 Research Program HRD+ Tumors....Lead candidate selection expected in 2022"

Clinical • Commercial • New P2 trial • New P3 trial • Oncology • Sarcoma • Solid Tumor

Rain Plans $100 Million IPO, Phase III Trial for Lead Precision Cancer Therapy (BioSpace) - “Newark, California-based cancer company Rain Therapeutics filed Friday for a $100 million IPO to advance its lead MDM2 inhibitor RAIN-32 into Phase III testing…The influx of cash will support a pivotal Phase III trial in liposarcoma, which Rain intends to launch this year, plus two more Phase II trials in solid tumors and intimal sarcoma, respectively…The company is aiming to select a lead clinical RAD52 inhibitor candidate in 2022.”

Financing • New P3 trial • Oncology • Sarcoma • Solid Tumor